Latest Breaking News On - Destiny breast08 - Page 1 : comparemela.com

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki demonstrated encouraging antitumor activity in patients with chemotherapy-naïve, HER2-low hormone receptor–positive metastatic breast cancer.

New yorkUnited statesMemorial sloan kettering cancer centerKomal jhaveriAntonio breast cancer symposiumTrastuzumab deruxtecanDestiny breast08